Dashboard
Manage Tickers

ANAB


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

barclays-maintains-overweight-on-anaptysbio-lowers-price-target-to-70
Barclays Maintains Overweight on AnaptysBi...
11/11/2025 14:55:17

Barclays analyst Etzer Darout maintains AnaptysBio (NASDAQ:ANAB) with a Overweight and lowers the price target from $83 to $70.

hc-wainwright--co-maintains-buy-on-anaptysbio-lowers-price-target-to-52
HC Wainwright & Co. Maintains Buy on Anapt...
11/11/2025 11:24:55

HC Wainwright & Co. analyst Emily Bodnar maintains AnaptysBio (NASDAQ:ANAB) with a Buy and lowers the price target from ...

anaptysbio-to-save-10-million-after-discontinuing-ulcerative-colitis-study
AnaptysBio To Save $10 Million After Disco...
11/10/2025 17:30:44

AnaptysBio ends its ulcerative colitis trial after rosnilimab misses key goals, focusing resources on rheumatoid arthritis and ...

truist-securities-maintains-hold-on-anaptysbio-raises-price-target-to-36
Truist Securities Maintains Hold on Anapty...
11/10/2025 16:11:06

Truist Securities analyst John Lee maintains AnaptysBio (NASDAQ:ANAB) with a Hold and raises the price target from $20 to $36.

trading-halt-halt-status-updated-at-94500-am-et-quotation-resumption-news-and-resumption-times
Trading Halt: Halt status updated at 9:45:...
11/10/2025 14:45:09

anaptys-phase-2-trial-of-rosnilimab-did-not-meet-primary-or-secondary-endpoints-at-week-12-in-moderate-to-severe-ulcerative-colitis-trial-to-be-discontinued
Anaptys Phase 2 Trial Of Rosnilimab Did No...
11/10/2025 14:03:07

trading-halt-halted-at-85500-am-et---trading-halt-halt-news-pending
Trading Halt: Halted at 8:55:00 a.m. ET - ...
11/10/2025 13:55:04

guggenheim-maintains-buy-on-anaptysbio-raises-price-target-to-100
Guggenheim Maintains Buy on AnaptysBio, Ra...
11/05/2025 15:07:06

Guggenheim analyst Yatin Suneja maintains AnaptysBio (NASDAQ:ANAB) with a Buy and raises the price target from $90 to $100.

wells-fargo-maintains-overweight-on-anaptysbio-raises-price-target-to-81
Wells Fargo Maintains Overweight on Anapty...
11/05/2025 14:56:51

Wells Fargo analyst Derek Archila maintains AnaptysBio (NASDAQ:ANAB) with a Overweight and raises the price target from $51 ...

anaptysbio-q3-eps-052-beats-142-estimate-sales-76320m-beat-15811m-estimate
AnaptysBio Q3 EPS $0.52 Beats $(1.42) Esti...
11/04/2025 21:38:56

AnaptysBio (NASDAQ:ANAB) reported quarterly earnings of $0.52 per share which beat the analyst consensus estimate of $(1.42) by...

stifel-maintains-buy-on-anaptysbio-raises-price-target-to-80
Stifel Maintains Buy on AnaptysBio, Raises...
10/29/2025 16:53:07

Stifel analyst Alex Thompson maintains AnaptysBio (NASDAQ:ANAB) with a Buy and raises the price target from $55 to $80.

anaptysbio-announces-late-breaking-data-from-global-424-patient-phase-2b-trial-of-rosnilimab-in-rheumatoid-arthritis-at-acr-convergence-2025
AnaptysBio Announces Late-Breaking Data Fr...
10/29/2025 13:19:06

New data reinforce rosnilimab's efficacy profile in rheumatoid arthritis (RA) with deepening of clinical responses, includi...

wedbush-maintains-outperform-on-anaptysbio-raises-price-target-to-70
Wedbush Maintains Outperform on AnaptysBio...
10/15/2025 15:11:02

Wedbush analyst David Nierengarten maintains AnaptysBio (NASDAQ:ANAB) with a Outperform and raises the price target from $45...

anaptysbio-says-complete-data-from-phase-2b-trial-of-rosnilimab-pathogenic-t-cell-depleter-in-ra-accepted-for-late-breaking-oral-presentation-at-acr-convergence-2025
AnaptysBio Says Complete Data From Phase 2...
10/13/2025 13:18:04

AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics...

barclays-initiates-coverage-on-anaptysbio-with-overweight-rating-announces-price-target-of-78
Barclays Initiates Coverage On AnaptysBio ...
10/13/2025 12:02:06

Barclays analyst Etzer Darout initiates coverage on AnaptysBio (NASDAQ:ANAB) with a Overweight rating and announces Price Ta...

anaptysbio-charts-path-to-split-into-two-public-companies-by-2026
AnaptysBio Charts Path To Split Into Two P...
09/30/2025 17:59:14

AnaptysBio plans to separate into Royalty Management Co. and Biopharma Co. by 2026, with each positioned for growth in distinct...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
09/30/2025 17:06:34

united-natural-foods-posts-upbeat-results-joins-anaptysbio-semtech-uipath-and-other-big-stocks-moving-higher-on-tuesday
United Natural Foods Posts Upbeat Results,...
09/30/2025 15:06:57

wedbush-reiterates-outperform-on-anaptysbio-maintains-45-price-target
Wedbush Reiterates Outperform on AnaptysBi...
09/30/2025 12:57:13

Wedbush analyst Martin Fan reiterates AnaptysBio (NASDAQ:ANAB) with a Outperform and maintains $45 price target.

hc-wainwright--co-maintains-buy-on-anaptysbio-raises-price-target-to-59
HC Wainwright & Co. Maintains Buy on Anapt...
09/30/2025 11:38:00

HC Wainwright & Co. analyst Emily Bodnar maintains AnaptysBio (NASDAQ:ANAB) with a Buy and raises the price target from ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION